tiprankstipranks
Trending News
More News >

DocMorris AG Shareholders Approve CHF 200 Million Capital Increase

Story Highlights
  • DocMorris AG’s shareholders approved a capital increase to raise CHF 200 million.
  • The capital increase aims to finance growth in prescription drugs and achieve positive cash flow by 2027.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

DocMorris ( (CH:DOCM) ) just unveiled an announcement.

DocMorris AG’s shareholders have approved a capital increase through a rights issue to raise approximately CHF 200 million, aimed at financing growth in prescription drugs and achieving positive cash flow by 2027. The capital increase will also support marketing expenses and potentially repay a CHF 95 million convertible bond. The rights issue involves offering new shares to existing shareholders and eligible investors, with trading and settlement scheduled for May 2025.

More about DocMorris

DocMorris AG is a prominent player in the online pharmacy, marketplace, and professional healthcare sectors, with a strong presence in Germany and other European countries. The company operates a highly automated logistics center in the Netherlands and leads the health and care products marketplace in Southern Europe. With a vision to create a digital health ecosystem, DocMorris serves over 10 million active customers and achieved external sales of CHF 1,085 million in 2024.

Average Trading Volume: 136,633

Current Market Cap: CHF315.6M

See more data about DOCM stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App